18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study

Journal of Bone and Mineral Research

Volumn 28, Issue 6, 2013, Pages 1337-1347

  Frost, Michelle L ^a   Moore, Amelia E ^a   Siddique, Musib ^a   Blake, Glen M ^a   Laurent, Didier ^b   Borah, Babul ^b   Schramm, Ursula ^b   Valentin, Marie Anne ^b   Pellas, Theodore C ^b   Marsden, Paul K ^c   Schleyer, Paul J ^c   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

18F FLUORIDE PET; BIOMARKER; BONE FORMATION; OSTEOPOROSIS; TREATMENT EFFICACY

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; FLUORINE 18; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; VITAMIN D; BONE DENSITY CONSERVATION AGENT; FLUORIDE; FLUORINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FEMUR; FEMUR NECK; FOREARM; HIP; HUMAN; LUMBAR SPINE; OSSIFICATION; OSTEOPENIA; PATIENT COMPLIANCE; PELVIS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BONE DISEASES, METABOLIC; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; PELVIC GIRDLE; RADIOGRAPHY; CONTROLLED CLINICAL TRIAL; METABOLIC BONE DISEASE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; FEMALE; FEMUR NECK; FLUORIDES; FLUORINE RADIOISOTOPES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; PELVIC BONES; POSITRON-EMISSION TOMOGRAPHY; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 84878263174     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1862     Document Type: Article

References (47)

1. Bouxsein ML, Delmas PD., Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008; 23 (8): 1155-67.
2. Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tankõ LB., An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol. 2006; 62: 781-92.
3. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B., Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001; 12: 989-95.
4. Burr DB., Cortical bone: a target for fracture prevention?. Lancet. 2010; 375: 1672-3.
5. Holzer G, von Skrbensky G, Holzer LA, Pichl W., Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res. 2009; 24: 468-74.
6. Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E., Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375: 1729-36.
7. Hartholt KA, Oudshoorn C, Zielinski SM, Burgers PT, Panneman MJ, van Beeck EF, Patka P, van der Cammen TJ., The epidemic of hip fractures: are we on the right track?. PLoS One. 2011; 6: e22227.
8. 18F-fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endo Metab. 1993; 77: 949-55.
9. 18F-fluoride PET: correlation with bone histomorphometry. J Nucl Med. 2001; 42: 1091-100.
10. Hawkins RA, Choi Y, Huang S-C, Hoh CK, Dahlbom M, Schiepers C, Satyamurthy N, Barrio JR, Phelps ME., Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992; 33: 633-42.
11. 18F- fluoride PET for measuring regional bone metabolism: a comparison of quantification methods. J Nucl Med. 2011; 52: 1748-55.
12. 18F- fluoride positron emission tomography. J Bone Miner Res. 2002; 17: 854-9.
13. Frost ML, Fogelman I, Blake GM, Marsden PK, Fogelman I., Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis. J Bone Miner Res. 2004; 19: 1797-804.
14. 18F-fluoride PET study of treatment-naïve and treated postmenopausal women. Bone. 2009; 45: 942-8.
15. 18F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med. 2005; 46: 1650-8.
16. 18F-fluoride ion PET and quantitative CT. J Nucl Med. 2003; 44: 117-24.
17. Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M., Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997; 38: 1970-6.
18. 18F-fluoride ion and dynamic positron emission tomography. Eur J Nucl Med. 1995; 22: 1133-40.
19. 18F-fluoride PET scans. J Nucl Med. 2004; 45: 1493-500.
20. 18F-FDG PET scans to assess fracture healing in a rat femur model. Eur J Nucl Med Mol Imaging. 2007; 34: 1291-301.
21. 18F-fluoride ion positron emission tomography. Eur J Nucl Med. 1999; 26: 615-24.
22. 18F-fluoride positron emission tomography. J Bone Miner Res. 2003; 18: 2215-22.
23. 18F-fluoride positron emission tomography. J Bone Miner Res. 2011; 26: 1002-11.
24. 18F-fluoride PET: a prospective study. J Nucl Med. 2009; 50: 1808-14.
25. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Support Series, No 843 Geneva, Switzerland: WHO, 1994.
26. Cook GJR, Lodge MA, Marsden PK, Dynes A, Fogelman I., Non-invasive assessment of skeletal kinetics using fluorine-18-fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. Eur J Nuc Med. 1999; 26: 1424-9.
27. 18F-fluoride PET scans. Nucl Med Commun. 2012; 33: 881-8.
28. Patlak CS, Blasberg RG, Fenstermacher JD., Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3: 1-7.
29. 18F- Fluoride PET Static Images. Eur J Nuc Med Mol Imaging. 2012; 39: 337-43.
30. Moore AE, Blake GM, Taylor KA, Rana AE, Wong M, Chen P, Fogelman I., Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res. 2010; 25: 960-7.
31. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH., Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004; 19: 623-9.
32. Bjørnerem Å, Ghasem-Zadeh A, Bui M, Wang X, Rantzau C, Nguyen TV, Hopper JL, Zebaze R, Seeman E., Remodeling markers are associated with larger intracortical surface area but smaller trabecular surface area: a twin study. Bone. 2011; 49: 1125-30.
33. Dalstra M, Huiskes R., Load transfer across the pelvic bone. J Biomechanics. 1995; 28: 715-24.
34. Hagino H, Okano T, Akhter MP, Enokida M, Teshima R., Effect of parathyroid hormone on cortical bone response to in vivo external loading of the rat tibia. J Bone Miner Metab. 2001; 19: 244-50.
35. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ., PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349: 1207-15.
36. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC., Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res. 2010; 25: 472-81.
37. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F., Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350: 550-5.
38. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH., Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med. 2001; 344: 1434-41.
39. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM., Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006; 91: 1370-5.
40. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R., Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003; 88: 5212-20.
41. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP., Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85: 3069-76.
42. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL., Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18: 539-43.
43. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM., Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16: 157-65.
44. Burr DB., Does early PTH treatment compromise bone strength? The balance between remodelling, porosity, bone mineral, and bone size. Curr Osteoporos Rep. 2005; 3: 19-24.
45. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF., Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932-41.
46. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ., PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005; 353: 555-65.
47. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I., Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31: 28-49.